Finance
Sino biopharm unit licenses blood cancer drug to sanofi for up to $1.53 billion
Published by Global Banking & Finance Review®
Posted on March 3, 2026
2 min readLast updated: March 3, 2026
Quick Summary
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has licensed global rights to rovadicitinib—an oral JAK/ROCK inhibitor for blood cancers, recently approved in China—to Sanofi for an upfront $135 million and up to $1.40 billion in milestones.
Sino Biopharm Signs $1.53B Global Blood Cancer Drug Deal with Sanofi
Major Licensing Agreement Expands Global Access to Blood Cancer Drug
Deal Overview and Financial Terms
March 4 (Reuters) - Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has signed an exclusive global licensing deal with French drugmaker Sanofi worth up to $1.53 billion, giving the European pharma giant rights to a blood cancer drug that won Chinese regulatory approval last month.
Exclusive Licensing and Upfront Payment
Under the agreement, Sino Biopharmaceutical's subsidiary Chia Tai Tianqing Pharmaceutical Group will grant Sanofi an exclusive worldwide licence to develop, manufacture and commercialise rovadicitinib, receiving an upfront payment of $135 million.
Milestone Payments
The company is also eligible to receive potential development, regulatory and sales milestone payments of up to $1.40 billion.
About Rovadicitinib
Mechanism of Action
Rovadicitinib is an oral drug that simultaneously targets inflammation and tissue scarring, two hallmarks of the diseases it is designed to treat.
JAK/ROCK Inhibitors
It belongs to a class of drugs known as JAK/ROCK inhibitors, which work by blocking enzymes that drive both processes.
Deal Conditions and Reporting
Regulatory Approvals
The deal is subject to customary closing conditions, including regulatory clearances, Sino Biopharmaceutical said.
Reporting Credits
(Reporting by Shivangi Lahiri in Bengaluru; Editing by Tasim Zahid)
Key Takeaways
- •Rovadicitinib, the drug licensed, is a first-in-class oral JAK/ROCK inhibitor that received Chinese approval in early March 2026 as a first‑line treatment for intermediate‑2 and high‑risk myelofibrosis, with strong efficacy and safety demonstrated versus hydroxyurea (minichart.com.sg).
- •Under the deal, Sino Biopharm’s unit gets $135 million upfront, plus up to $1.40 billion in development, regulatory and sales milestones, totaling as much as $1.53 billion (minichart.com.sg).
- •This agreement aligns with recent high-value licensing trends in the Chinese biotech sector—amid a flurry of deals by AbbVie, AstraZeneca, Sanofi and others—underscoring international pharma’s intensifying focus on China‑originated assets (fiercepharma.com).
References
Frequently Asked Questions about Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion
1What is the value of the Sino Biopharm and Sanofi licensing deal?
The deal is worth up to $1.53 billion, including an upfront payment of $135 million and potential milestone payments.
2Which drug is being licensed in this agreement?
The drug is rovadicitinib, an oral blood cancer treatment recently approved by Chinese regulators.
3Who is the subsidiary involved in the licensing deal with Sanofi?
Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical, is granting the licence.
4What class of drugs does rovadicitinib belong to?
Rovadicitinib belongs to the class of JAK/ROCK inhibitors.
5Is the licensing deal subject to any conditions?
Yes, the deal is subject to customary closing conditions, including regulatory clearances.
